Tandem Diabetes Care, Inc. reported $1.04B of revenue over the trailing twelve months, +4.0% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.04B (to Q2 2026). Net income: −$63M, trailing twelve months to Q2 2026. Free cash flow: −$27M, trailing twelve months to Q2 2026. Operating margin: −4.7%, trailing twelve months to Q2 2026.

TNDMTandem Diabetes Care, Inc.

Healthcare

$16.12+28% 1Y

$16.12

$11.7952 weeks$28.26

TNDM as reported

Tandem Diabetes Care, Inc. reported $1.04B of revenue over the trailing twelve months, +4.0% on the year before. 10 reported series are charted on this page, each one as filed.

$1.04B

Revenue, trailing twelve months · to Q2 2026 · +4.0% against the twelve months before

Net income: −$63M
Net income · −69% year on year · trailing twelve months to Q2 2026
Free cash flow: −$27M
Free cash flow · +243% year on year · trailing twelve months to Q2 2026
Operating margin: −4.7%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for TNDM, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.04B	+4.0%	Q2 2026
Net income	−$63M	−69%	Q2 2026
EPS	−$0.93	−70%	Q2 2026
Gross margin	56%	n/a	Q2 2026
Operating margin	−4.7%	n/a	Q2 2026
Net margin	−6.3%	n/a	Q2 2026
ROE	−101%	n/a	Q2 2026
ROA	−15%	n/a	Q2 2026
ROIC	−66%	n/a	Q2 2026
Free cash flow	−$27M	+243%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.